The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironment

Pancreatic ductal adenocarcinoma (PDAC) is a common malignant tumor of the digestive tract. Although gemcitabine and other therapeutic agents are effective in patients with advanced and metastatic pancreatic cancer, drug resistance has severely limited their use. However, the mechanisms of gemcitabine resistance in pancreatic cancer are poorly understood. In this study, ATAC-seq, ChIP-seq, and RNA-seq were performed to compare chromatin accessibility and gene expression in a patient-derived tumor xenograft (PDX) model of pancreatic cancer with or without gemcitabine resistance. Analyzing these sequencing data, we found a dramatic change in chromatin accessibility in the PDX model of gemcitabine-resistant tissues and identified a key gene, UBR7, which plays an important role in mediating gemcitabine resistance. Further research found that depletion of UBR7 significantly increased pancreatic carcinogenesis and the immunosuppressive microenvironment. Mechanistically, depleted UBR7 increased the stability of PRMT5, thereby promoting glycolysis in pancreatic cancer cells. Finally, an inhibitor that blocks PRMT5 (DS-437) significantly reduced gemcitabine resistance in pancreatic cancer caused by UBR7 depletion. In conclusion, our results illustrate that the UBR7-PRMT5 axis is a key metabolic regulator of PDAC and a promising target for the clinical treatment of gemcitabine resistance in PDAC.

• Publication year

  2024

• Venue

  Cell Death and Disease

• Publication date

  2024-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41419-024-07145-zPMID 39424627PMCID 11489413
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MCT4 blockade increases the efficacy of immune checkpoint blockade

  2023cited by this paper
• Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack

  2022cited by this paper
• Molecular characterization of substrate‐induced ubiquitin transfer by UBR7‐PHD finger, a newly identified histone H2BK120 ubiquitin ligase

  2021cited by this paper
• Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more.

  2021cited by this paper
• NOTCH1-driven UBR7 stimulates nucleotide biosynthesis to promote T cell acute lymphoblastic leukemia

  2021cited by this paper
• Targeting epigenetic regulatory machinery to overcome cancer therapy resistance.

  2021cited by this paper
• Formation of novel N-acetylcysteine-hemin adducts abrogates hemin-induced cytotoxicity and suppresses the NRF2-driven stress response in human pro-erythroid K562 cells.

  2020cited by this paper
• Immunotherapy for pancreatic cancer: A 2020 update.

  2020cited by this paper
• Tailored Chemodynamic Nanomedicine Improves Pancreatic Cancer Treatment via Controllable Damaging Neoplastic Cells and Reprogramming Tumor Microenvironment.

  2020cited by this paper
• Pancreatic cancer

  2020cited by this paper
• LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes

  2020cited by this paper
• The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities

  2020cited by this paper
• PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXRα/NF-κBp65 Pathway

  2020cited by this paper
• Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy

  2020cited by this paper
• Protein Arginine Methyltransferase 5 in T Lymphocyte Biology.

  2020cited by this paper
• Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.

  2020cited by this paper
• Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance.

  2019cited by this paper
• TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy.

  2019cited by this paper
• Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway

  2019cited by this paper
• Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor

  2019cited by this paper
• PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis

  2019cited by this paper
• Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment.

  2019cited by this paper
• The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis

  2019cited by this paper
• Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors.

  2019cited by this paper
• Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.

  2019cited by this paper
• Emerging trends in the immunotherapy of pancreatic cancer.

  2018cited by this paper
• Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling

  2018cited by this paper
• Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.

  2018cited by this paper
• Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis

  2017cited by this paper
• Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth.

  2016cited by this paper
• Integrative analysis of 111 reference human epigenomes

  2015cited by this paper
• Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants

  2015cited by this paper
• Modification of enhancer chromatin: what, how, and why?

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.

  2012cited by this paper
• A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

  2010cited by this paper
• The type III TGF-beta receptor suppresses breast cancer progression.

  2007cited by this paper
• Human SWI/SNF-Associated PRMT5 Methylates Histone H3 Arginine 8 and Negatively Regulates Expression of ST7 and NM23 Tumor Suppressor Genes

  2004cited by this paper

• Roles of E3 ubiquitin ligases and deubiquitinating enzymes in renal cell carcinoma

  2026cites this paper
• PRMT5 inhibitors: Therapeutic potential in pancreatic cancer

  2025cites this paper
• The E3 Ligase NEDD4L Prevents Colorectal Cancer Liver Metastasis via Degradation of PRMT5 to Inhibit the AKT/mTOR Signaling Pathway

  2025cites this paper
• Simultaneous Cholesterol Reduction and cGAS-STING Pathway Amplification: A Novel Enzyme Cascade Strategy against Tumor Resistance.

  2025cites this paper
• A phosphorylation-driven ubiquitination switch fine-tunes Alfin-like 7–induced ROS signaling in plant immunity

  2025cites this paper
• Role of Ubiquitination-driven Metabolisms in Oncogenesis and Cancer Therapy.

  2025cites this paper
• Targeting IRF7 to overcome gemcitabine resistance in pancreatic ductal adenocarcinoma

  2025cites this paper
• Post-Translational Modifications: Key “Regulators” of Pancreatic Cancer Malignant Phenotype—Advances in Mechanisms and Targeted Therapies

  2025cites this paper
• Protein arginine methylation and ubiquitination: A prominent crosstalk and its functions in cancer

  2025cites this paper
• Nuclear Symmetric Dimethylarginine Staining is Indicative of Pancreatic Ductal Adenocarcinoma.

  2025cites this paper